Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

Completed

Conditions: Lung Cancer

Interventions: Genetic: obtain tissue specimens

First Posted Date: 2011-02-21

Last Posted Date: 2021-01-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01300429

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI

Withdrawn

Conditions: Breast Cancer

Interventions: Other: MRI

First Posted Date: 2011-02-16

Last Posted Date: 2012-11-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT01297231

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin
Drug: BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)
Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin
Drug: BKM120, Paclitaxel + Carboplatin

First Posted Date: 2011-02-16

Last Posted Date: 2017-03-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT01297452

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Phase 1

Completed

Conditions: Relapsed/Refractory Sarcomas
Solid Tumors

Interventions: Drug: Vorinostat and Etoposide

First Posted Date: 2011-02-11

Last Posted Date: 2021-11-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 27

Registration Number: NCT01294670

Locations: 🇺🇸
All Children's Hospital, Saint Petersburg, Florida, United States
🇺🇸
John Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 8 locations

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: pertuzumab in combination with trastuzumab and paclitaxel

First Posted Date: 2011-01-13

Last Posted Date: 2020-08-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 70

Registration Number: NCT01276041

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

and more 3 locations

Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls
Behavioral: Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction

First Posted Date: 2011-01-12

Last Posted Date: 2019-07-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 99

Registration Number: NCT01275404

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: STA-9090

First Posted Date: 2011-01-11

Last Posted Date: 2015-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT01273896

Locations: 🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Early Phase 1

Active, not recruiting

Conditions: Non-Hodgkin's Lymphoma
Myeloma
Active Solid Malignancy

Interventions: Drug: PET Imaging using 124 IPUH71

First Posted Date: 2011-01-04

Last Posted Date: 2025-01-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 63

Registration Number: NCT01269593

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma

Not Applicable

Completed

Conditions: HEAD & NECK Cancer

Interventions: Drug: ribavirin

First Posted Date: 2010-12-31

Last Posted Date: 2023-10-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT01268579

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

Not Applicable

Active, not recruiting

Conditions: Newly Diagnosed or Recurrent Metastatic Melanoma Patients
Malignant Brain Tumors

Interventions: Drug: PET scan with 124I-cRGDY-PEG-dots

First Posted Date: 2010-12-24

Last Posted Date: 2024-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT01266096

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy